Recurrence, progression and survival in @entity150 . A retrospective analysis of 232 XXXX with greater than or equal to 5-year follow-up.

@entity1 @entity7460 @entity5 @entity189 @entity150 @entity11090
A retrospective study of 232 @entity150 with minimum follow-up 5 years is presented. The @entity189 was superficial in 66%, muscle-invasive in 31% and could not be staged in 3%. Primary treatment was mainly transurethral resection for superficial @entity5 , but was cystectomy or radiotherapy in 22 of 29 T1 G3. Of the superficial @entity5 , 71% recurred. Progression to higher T stage occurred in 15% of Ta and 29% of T1 @entity5 , and half of these @entity1 died of @entity150 . The corrected 5-year survival rates in grades 1, 2A, 2B and 3-4 were 96, 84, 64 and 43%, and in stages Ta, T1, T2 and T3 they were 94, 69, 40 and 31%. All @entity1 with T4 @entity5 died within 4 years. Among the 45 @entity1 with 40 Gy irradiation + cystectomy, the corrected 5-year survival rate was 83% in superficial and 64% in @entity5 , and among the 38 with radical radiotherapy the rates in @entity7460 were 46, 36 and 13%. Transurethral resection was successful in most Ta cases. Most T1 @entity5 were, like T2-4, of higher grade than Ta. Prognosis was worse in T1 than in Ta. After progression to @entity11090 , even during close follow-up the outlook was poor, as poor as for @entity1 with primary @entity11090 .
